Drugs that disrupt VEGF signaling are being used to treat a range of retinal diseases, including neovascular age-related macular degeneration (NVAMD), diabetic macular edema, and retinal vein occlusion. This evidence concerns the gene VEGFA and retinal vein occlusion.